Atrasentan HCl
Atrasentan HCl is an endothelin receptor antagonist (IC50=0.0551 nM, ETA) being developed for the treatment of prostate cancer.
| Trivial name | ABT-627; Abbott-147627 |
| Catalog Number | CSN13753 |
| Alternative Name(s) | ABT-627; Abbott-147627 |
| Research Area | Cancer |
| Molecular Formula | C29H39ClN2O6 |
| CAS# | 195733-43-8 |
| Purity | ≥99% |
| SMILES | O=C([C@H]1[C@H](C2=CC=C(OC)C=C2)N(CC(N(CCCC)CCCC)=O)C[C@@H]1C3=CC=C(OCO4)C4=C3)O.[H]Cl |
| Size | 2mg |
| Supplier Page | https://www.csnpharm.com/products/atrasentan-hcl.html |